Efficacy and Safety of Polymyxin E Sulfate in the Treatment of Critically Ill Patients with Carbapenem-resistant Organism Infections

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Jan 16

PMID 36643845

Authors

Xin Lu

Cejun Zhong

Yanbin Liu

Hui Ye

Junyan Qu

Zhiyong Zong

Xiaoju Lv

Affiliations

Soon will be listed here.

Abstract

Objective: Polymyxins are currently the last line of defense in the treatment of carbapenem-resistant organisms (CRO). As a kind of polymyxin available for clinical use in China, we aim to explore the efficacy and safety of colistin sulfate (Polymyxin E sulfate, PES) in this study.

Methods: This real-world retrospective study included 119 patients diagnosed with CRO infection and treated with PES for more than 72 h, from May 2020 to July 2022 at West China Hospital. The primary outcome was clinical efficacy at the end of treatment, and secondary outcomes included microbial response, in-hospital mortality and incidence of nephrotoxicity.

Results: The effective clinical and microbiological responses were 53.8% and 49.1%, respectively. And the in-hospital mortality was 27.7%. Only 9.2% of patients occurred with PES-related nephrotoxicity. Multivariate analysis revealed that duration of PES was an independent predictor of effective therapy, while age-adjusted Charlson comorbidity index (aCCI) and post-treatment PCT(p-PCT) were independent risk factors for poor outcome.

Conclusions: PES can be a salvage treatment for CRO-induced infections with favorable efficacy and low nephrotoxicity. The treatment duration of PES, aCCI and p-PCT were factors related to the clinical effectiveness of PES.

Citing Articles

Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study.

Zhang Y, Wang C, Chen J, Bai C, Sun D, Qiu Y Front Pharmacol. 2025; 15():1466888.

PMID: 39830357 PMC: 11739331. DOI: 10.3389/fphar.2024.1466888.

Clinical Effectiveness and Safety of Colistin Sulphate in Treating Infections Caused by Carbapenem-Resistant Organisms and Analysis of Influencing Factors.

Ma Y, Sun Y, Wu X, Wang Y, Yang X, Gu J Infect Drug Resist. 2024; 17:3793-3804.

PMID: 39247753 PMC: 11380488. DOI: 10.2147/IDR.S473200.

Development and validation of a prognostic nomogram to predict 30-day all-cause mortality in patients with CRO infection treated with colistin sulfate.

Li W, Liu Y, Xiao L, Cai X, Gao W, Xu D Front Pharmacol. 2024; 15:1409998.

PMID: 39101134 PMC: 11294994. DOI: 10.3389/fphar.2024.1409998.

Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases.

Wu Y, Jiang S, Li D, Wu Y, Li Q, Wang X Infect Dis Ther. 2024; 13(1):141-154.

PMID: 38212555 PMC: 10828183. DOI: 10.1007/s40121-023-00909-8.

Nephrotoxicity caused by colistin use in ICU: a single centre experience.

Kilic I, Ayar Y, Ceylan I, Kucukdemirci Kaya P, Caliskan G BMC Nephrol. 2023; 24(1):302.

PMID: 37833622 PMC: 10576281. DOI: 10.1186/s12882-023-03334-8.

References

Pan S, Huang X, Wang Y, Li L, Zhao C, Yao Z . Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR : a retrospective cohort study. Antimicrob Resist Infect Control. 2018; 7:8. PMC: 5775564. DOI: 10.1186/s13756-018-0305-5. View

Liang Q, Huang M, Xu Z . Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019; 23(1):60-65. PMC: 9428011. DOI: 10.1016/j.bjid.2018.12.004. View

Xie Y, Jin X, Yan S, Wu C, Xiang B, Wang H . Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients. Front Pharmacol. 2022; 13:967412. PMC: 9465641. DOI: 10.3389/fphar.2022.967412. View

Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic J, Lye D, Lee L . Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2017; 104(3):534-538. DOI: 10.1002/cpt.981. View

Yang Q, Ma X, Hu F, Zhang J, Sun T, Chen B . Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation. Chin Med Sci J. 2021; 36(1):1-16. DOI: 10.24920/003864. View

Schuetz P, Albrich W, Mueller B . Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011; 9:107. PMC: 3186747. DOI: 10.1186/1741-7015-9-107. View

Chen W, Lin L, Wang X, Kong X, Guo L, Zhao L . Respiratory arrest associated with polymyxin B in a lung transplant patient. Chin Med J (Engl). 2020; 133(11):1375-1377. PMC: 7289288. DOI: 10.1097/CM9.0000000000000826. View

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet D . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017; 18(3):318-327. DOI: 10.1016/S1473-3099(17)30753-3. View

Lin Y, Zhou Q, Onufrak N, Wirth V, Chen K, Wang J . Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother. 2017; 61(8). PMC: 5527630. DOI: 10.1128/AAC.00211-17. View

10.

Ziaka M, Markantonis S, Fousteri M, Zygoulis P, Panidis D, Karvouniaris M . Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother. 2013; 57(4):1938-40. PMC: 3623300. DOI: 10.1128/AAC.01461-12. View

11.

Peng D, Zhang F, Lv P, Chen Y, Yang J, Zhu W . Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report. Ann Transl Med. 2022; 10(10):614. PMC: 9201130. DOI: 10.21037/atm-22-2081. View

12.

. [Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China]. Zhonghua Jie He He Hu Xi Za Zhi. 2021; 44(4):292-310. DOI: 10.3760/cma.j.cn112147-20201109-01091. View

13.

Falagas M, Kyriakidou M, Voulgaris G, Vokos F, Politi S, Kechagias K . Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence. J Glob Antimicrob Resist. 2021; 24:342-359. DOI: 10.1016/j.jgar.2020.12.026. View

14.

Xia G, Jiang R . Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections. BMC Infect Dis. 2021; 21(1):1034. PMC: 8488323. DOI: 10.1186/s12879-021-06719-y. View

15.

Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55(7):3284-94. PMC: 3122440. DOI: 10.1128/AAC.01733-10. View

16.

Falagas M, Kasiakou S . Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006; 10(1):R27. PMC: 1550802. DOI: 10.1186/cc3995. View

17.

Kellum J, Lameire N . Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013; 17(1):204. PMC: 4057151. DOI: 10.1186/cc11454. View

18.

Michalopoulos A, Karatza D, Gregorakos L . Pharmacokinetic evaluation of colistin sodium. Expert Opin Drug Metab Toxicol. 2010; 7(2):245-55. DOI: 10.1517/17425255.2011.541439. View

19.

F John J, Falci D, Rigatto M, Oliveira R, Kremer T, Zavascki A . Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740322. DOI: 10.1128/AAC.01617-17. View

20.

Tsuji B, Pogue J, Zavascki A, Paul M, Daikos G, Forrest A . International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of.... Pharmacotherapy. 2019; 39(1):10-39. PMC: 7437259. DOI: 10.1002/phar.2209. View